SMARCA2 and hematocrit: We also demonstrate that HT patients (heterozygous for SMARCA2 rs10738556) have decreased SMARCA2 expression, albeit without reaching statistical significance, and significantly increased apoptosis in comparison to controls (Fig. 3B, Supplementary Fig. 4).